Physician profile
Kati Mathis
NPI 1932727625
$3,459.48
in general payments reported to CMS, 2019-2025
23 companies · $1,069 in 2025
The $1,069 reported for 2025 was more than what 86% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $446 · 2023: $950 · 2024: $993 · 2025: $1,069.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,013.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,013.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $710.71 | 2022-2025 | |
| Amgen INC. | $398.77 | 2022-2025 | Enbrel, Otezla, Krystexxa |
| Janssen Biotech, INC. | $355.00 | 2022-2025 | Tremfya, Simponi Aria |
| Glaxosmithkline, LLC. | $338.40 | 2023-2025 | Benlysta |
| Astrazeneca Pharmaceuticals LP | $296.27 | 2022-2025 | Saphnelo |
| Ani Pharmaceuticals, INC. | $245.88 | 2023-2025 | Purified Cortrophin Gel |
| Ucb, INC. | $109.86 | 2023-2025 | Cimzia, Bimzelx |
| Pfizer INC. | $105.84 | 2024-2025 | |
| Janssen Scientific Affairs, LLC | $102.35 | 2022-2023 | Tremfya |
| Organon LLC | $96.33 | 2024-2025 | Hadlima |
| Pharming Healthcare, INC. | $85.04 | 2022-2023 | Ruconest |
| Alexion Pharmaceuticals, INC. | $84.71 | 2022-2025 | Strensiq |
| Mallinckrodt Hospital Products INC. | $70.73 | 2023-2025 | Acthar |
| Tersera Therapeutics LLC | $70.36 | 2023-2025 | Quzyttir |
| Takeda Pharmaceuticals U.S.A., INC. | $64.00 | 2025 | Hyqvia |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sobi, INC | $58.92 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $57.32 | 2023 | |
| Lilly USA, LLC | $56.70 | 2022 | |
| Radius Health, INC. | $54.16 | 2025 | Tymlos |
| Aurinia Pharma U.S., INC. | $42.74 | 2023-2025 | Lupkynis |
| Celgene Corporation | $22.59 | 2024 | Orencia |
| Scilex Pharmaceuticals INC. | $17.97 | 2024 | |
| Horizon Therapeutics Plc | $14.83 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kati Mathis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.